Last reviewed · How we verify

NCT04410718: GLYCOVID-19

Glycaemia and Cardiac Function in Patients With COVID-19

Completed Last updated 29 November 2022
What this trial tests

trial testing Glycaemic levels in Diabetes Mellitus in 50 participants. Completed in 30 June 2021.

Timeline
20 April 2020
Primary endpoint
30 June 2021
30 June 2021

Quick facts

Lead sponsorSteno Diabetes Center Copenhagen
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date20 April 2020
Primary completion30 June 2021
Estimated completion30 June 2021
Sites2 locations across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Steno Diabetes Center Copenhagen — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study design is observational, exploratory study consisting of two cohorts of COVID-19 patients admitted to the ICU and the medical ward, respectively. The primary outcome focusing on the effect of plasma glucose levels on cardiac function will be evaluated by repeated assessment of cardiac function by echocardiography and measurement of plasma glucose. Furthermore, blood coagulability will be evaluated to determine the importance of diabetes status and plasma glucose changes for whole blood coagulability at time of admission to the ICU and progression in coagulability abnormalities. In the medical ward cohort, two assessments will be performed separated by no more than 12 hours. In the ICU cohort, three assessments will be performed separated by no more than 6 hours. Ideally, 60 patients with COVID-19 will be included in the ICU cohort with a 1:1 distribution between patient with and without diabetes. Ideally, 40 patients with diabetes will be included in the cohort of patients admitted to medical ward (hospitalisation cohort). The primary hypothesis is that levels of plasma glucose have clinically significant impact on left ventricular systolic function in patients with COVID-19 admitted to the ICU. The secondary hypothesis is that the impact of plasma glucose on left ventricular systolic function is associated with glycaemic control prior to admission as measured by HbA1c.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Steno Diabetes Center Copenhagen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04410718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing